IL-12 as an adjuvant for the enhancement of protective humoral immunity

Expert Review of Vaccines

Volumn 8, Issue 5, 2009, Pages 515-518

  Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; MENINGOCOCCUS VACCINE; PHOSPHATE BUFFERED SALINE; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; VACCINE;

ACUTE OTITIS MEDIA; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BACTERIAL COLONIZATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISULFIDE BOND; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRANCISELLA TULARENSIS; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS; LUNG INFECTION; MOLECULAR WEIGHT; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PLAGUE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TH1 CELL; TH2 CELL; TULAREMIA; UNSPECIFIED SIDE EFFECT; VACCINATION; YERSINIA PESTIS; ADULT; IMMUNOLOGY;

ADULT; ANTIBODY FORMATION; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; VACCINES; YOUNG ADULT;

EID: 65649108409     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.13     Document Type: Editorial

References (35)

1. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Mucosal Immunology (3rd Edition). Mestecky J, Lamm ME, Strober W et al. (Eds). Elsevier Academic Press, Amsterdam, The Netherlands 967-986 (2005).
2. Liang XP, Lamm ME, Nedrud JG. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice. Reg. Immunol. 2, 244-248 (1989).
3. Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61, 314-322 (1993). (Pubitemid 23015433)
4. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's Palsy. N. Engl. J. Med. 350(9), 860-861 (2004). (Pubitemid 38252532)
5. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155(10), 4621-4629 (1995).
6. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189(3), 541-552 (1999). (Pubitemid 29187376)
7. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3(2), 133-146 (2003). (Pubitemid 37328691)
8. Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24(4), 207-212 (2003). (Pubitemid 36412109)
9. Buchanan JM, Vogel LA, Van Cleave VH, Metzger DW. Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int. Immunol. 7(9), 1519-1528 (1995).
10. Metzger DW, Buchanan JM, Collins JT et al. Enhancement of humoral immunity by interleukin-12. Ann. NY Acad. Sci. 795, 100-115 (1996). (Pubitemid 27029559)
11. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J. Immunol. 152, 2172-2179 (1994). (Pubitemid 24097905)
12. Germann T, Bongartz M, Dlugonska H et al. Interleukin-12 profoundly upregulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b, and IgG3 antibody subclasses in vivo. Eur. J. Immunol. 25, 823-829 (1995).
13. Morris SC, Madden KB, Adamovicz JJ et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 152, 1047-1056 (1994). (Pubitemid 24134329)
14. Bliss J, Van Cleave V, Murray K et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156(3), 887-894 (1996). (Pubitemid 26048079)
15. Vogel LA, Showe LC, Lester TL et al. Direct binding of IL-12 to human and murine B lymphocytes. Int. Immunol. 8(12), 1955-1962 (1996). (Pubitemid 27007746)
16. Jones D, Elloso MM, Showe L et al. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect. Immun. 66(8), 3818-3824 (1998). (Pubitemid 28347842)
17. Airoldi I, Gri G, Marshall JD et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J. Immunol. 165(12), 6880-6888 (2000). (Pubitemid 32001157)
18. Jelinek DF, Braaten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J. Immunol. 154, 1606-1613 (1995).
19. Yoshimoto T, Okamura H, Tagawa Y-I, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc. Natl Acad. Sci. USA 94, 3948-3953 (1997). (Pubitemid 27180479)
20. Thibodeaux DK, Hunter SE, Waldburger KE et al. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-γ secretion and not restricted to T and NK cells. J. Immunol. 163(10), 5257-5264 (1999).
21. Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback tegulation of Th1 development. J. Immunol. 163(8), 4284-4291 (1999). (Pubitemid 29474494)
22. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180(4), 940-949 (1999). (Pubitemid 30070172)
23. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69(11), 6718-6724 (2001). (Pubitemid 32995429)
24. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71(8), 4780-4788 (2003). (Pubitemid 36919948)
25. Sun K, Johansen FE, Eckmann L, Metzger DW. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J. Immunol. 173(7), 4576-4581 (2004). (Pubitemid 39280690)
26. Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an IgA-dependent fashion. Infect. Immun. 75(5), 2152-2162 (2007). (Pubitemid 46744301)
27. Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine 17(3), 252-260 (1999). (Pubitemid 28552785)
28. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J. Immunol. 161(10), 5525-5533 (1998). (Pubitemid 28519116)
29. Metzger DW, McNutt RM, Collins JT et al. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-γ-dependent and -independent mechanisms. Eur. J. Immunol. 27(8), 1958-1965 (1997). (Pubitemid 27346011)
30. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166(12), 7381-7388 (2001). (Pubitemid 32525614)
31. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69(11), 6718-6724 (2001). (Pubitemid 32995429)
32. Buchanan RM, Briles DE, Arulanandam BP et al. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 19(15-16), 2020-2028 (2001). (Pubitemid 32178351)
33. Andersson Å, Dai WJ, Di Santo JP, Brombacher F. Early IFN-γ production and innate immunity during Listeria monocytogenes infection in the absence of NK cells. J. Immunol. 161(10), 5600-5606 (1998).
34. Hedlund J, Langer B, Konradsen HB, Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 20(1-2), 164-169 (2001). (Pubitemid 32905329)
35. Huber VC, Arulanandam BP, Arnaboldi PM et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 3(6), 801-809 (2003). (Pubitemid 36629446)